BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scavone C, di Mauro G, Mascolo A, Berrino L, Rossi F, Capuano A. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Front Pharmacol 2019;10:111. [PMID: 30814951 DOI: 10.3389/fphar.2019.00111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Hughes RE, Elliott RJR, Dawson JC, Carragher NO. High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. Cell Chem Biol 2021;28:338-55. [PMID: 33740435 DOI: 10.1016/j.chembiol.2021.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Appl Health Econ Health Policy 2020;18:5-16. [PMID: 31696433 DOI: 10.1007/s40258-019-00527-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
3 Lee Y, Chao Y, Lin P, Yang Y, Yang Y, Chu C, Wang Y, Chang C, Chuang S, Chen W, Sun H, Tsou H, Chou C, Yang W. Quality assurance of integrative big data for medical research within a multihospital system. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2021.12.024] [Reference Citation Analysis]
4 Hassan KM, Njogu PM, Njuguna NM, Ndwigah SN. Microbiological contamination of herbal medicinal products marketed in Kenya for chronic diseases: A case study of Nairobi metropolis. Journal of Herbal Medicine 2021;29:100475. [DOI: 10.1016/j.hermed.2021.100475] [Reference Citation Analysis]
5 Leo CP, Hentschel B, Szucs TD, Leo C. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis. Cancers (Basel) 2020;12:E437. [PMID: 32069837 DOI: 10.3390/cancers12020437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
6 Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. Rheumatol Ther 2019;6:317-38. [PMID: 31385263 DOI: 10.1007/s40744-019-00169-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Bloem LT, Vreman RA, Peeters NWL, Hoekman J, van der Elst ME, Leufkens HGM, Klungel OH, Goettsch WG, Mantel-Teeuwisse AK. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clin Transl Sci 2021;14:1566-77. [PMID: 33786991 DOI: 10.1111/cts.13027] [Reference Citation Analysis]
8 Woods N, MacLoughlin R. Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease. Pharmaceutics 2020;12:E922. [PMID: 32993197 DOI: 10.3390/pharmaceutics12100922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Filimonov DA, Rudik AV, Dmitriev AV, Poroikov VV. Computer-Aided Estimation of Biological Activity Profiles of Drug-Like Compounds Taking into Account Their Metabolism in Human Body. Int J Mol Sci 2020;21:E7492. [PMID: 33050610 DOI: 10.3390/ijms21207492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ruggiero R, Motta G, Massaro G, Rafaniello C, Della Corte A, De Angelis A, Capuano A, Motta G, Rossi F. Pharmacological, Technological, and Digital Innovative Aspects in Rhinology. Front Allergy 2021;2:732909. [DOI: 10.3389/falgy.2021.732909] [Reference Citation Analysis]
11 Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Front Pharmacol 2020;11:420. [PMID: 32390828 DOI: 10.3389/fphar.2020.00420] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
12 Fader KA, Zhang J, Menetski JP, Thadhani RI, Antman EM, Friedman GS, Ramaiah SK, Vaidya VS. A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic. J Pharmacol Exp Ther 2021;376:12-20. [PMID: 33115823 DOI: 10.1124/jpet.120.000204] [Reference Citation Analysis]
13 Das T, Das TK, Khodarkovskaya A, Dash S. Non-coding RNAs and their bioengineering applications for neurological diseases. Bioengineered 2021. [PMID: 34756133 DOI: 10.1080/21655979.2021.2003667] [Reference Citation Analysis]
14 Hao P, Wu L, Liu Y. A survey on work status and competencies of Clinical Research Nurses in China. Journal of Research in Nursing 2022;27:82-98. [DOI: 10.1177/17449871211067963] [Reference Citation Analysis]
15 Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, Ferrajolo C, Rafaniello C, Sportiello L, Rossi F, Capuano A. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol 2020;11:830. [PMID: 32581796 DOI: 10.3389/fphar.2020.00830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Iskrov G, Vasilev G, Stefanov R. What could gene therapies learn from orphan drugs’ post-regulatory approval access in the EU? Expert Opinion on Orphan Drugs 2019;7:407-14. [DOI: 10.1080/21678707.2019.1663171] [Reference Citation Analysis]
17 Mirones I, Moreno L, Patiño-García A, Lizeaga G, Moraleda JM, Toribio ML, Pérez-Martínez A; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas., Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas. [Immunotherapy with CAR-T cells in paediatric haematology-oncology]. An Pediatr (Engl Ed) 2020;93:59.e1-59.e10. [PMID: 32107177 DOI: 10.1016/j.anpedi.2019.12.014] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jansen E, Hines PA, Berntgen M, Brand A. Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.026] [Reference Citation Analysis]